Baseline clinical characteristics of the study population
| Variable | Bivalirudin (n=1928) | Bivalirudin + UFH (n=1068) | p Value |
| Age (years) | 71.2 (63–81) | 70.0 (61–80) | 0.002 |
| Male sex | 1256 (65.1%) | 675 (63.2%) | 0.314 |
| Risk factors | |||
| Diabetes mellitus [60, 20] | 271 (14.5%) | 123 (11.7%) | 0.041 |
| Prior hyperlipidaemia [151, 65] | 422 (23.7%) | 220 (21.9%) | 0.306 |
| Prior hypertension [119, 52] | 792 (43.7%) | 426 (41.9%) | 0.361 |
| Current smoker [278, 99] | 448 (27.1%) | 271 (27.9%) | 0.687 |
| Previous CABG [2, 1] | 92 (4.7%) | 29 (2.8%) | 0.014 |
| Previous PCI [2, 1] | 186 (9.6%) | 101 (9.4%) | 0.929 |
| Prior MI [75, 42] | 331 (17.9%) | 136 (13.8%) | 0.006 |
Missing values are shown in square brackets.
CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention; UFH, unfractionated heparin.